<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, June 11 2019 (HealthDay News) — Genome-wide polygenic risk scores (PRS) can predict coronary artery disease (CAD), according to a study published online June 11 in Circulation: Genomic and Precision Medicine<\/i>.<\/p>\n
Noting that two recently derived genome-wide PRS have shown high specificity and sensitivity to identify CAD cases in European-ancestry participants from the U.K. Biobank, Florian W\u00fcnnemann, Ph.D., from the Montreal Heart Institute, and colleagues calculated both PRS (GPSCAD<\/sub> and metaGRSCAD<\/sub>) in French-Canadian individuals from three cohorts totaling 3,639 prevalent CAD cases and 7,382 controls. The impact of the founder French-Canadian familial hypercholesterolemia deletion (LDLR<\/i> delta > 15kb deletion) was estimated on CAD risk in one of these cohorts; this estimate was used to calibrate PRS impact.<\/p>\n The researchers confirmed the ability of both PRS to predict prevalent CAD comparable to the original reports (area under the curve [AUC], 0.72 to 0.89). Consistent with previous estimates, the PRS identified about 6 to 7 percent of individuals at CAD risk similar to that for carriers of the LDLR<\/i> delta > 15kb mutation. For predicting incident or recurrent CAD, the PRS did not perform as well (AUC, 0.56 to 0.60), possibly due to confounding as more than three-quarters (76 percent) of participants were on statin treatment.<\/p>\n “Using the polygenic risk score, even in a normal population, we can find people whose risk is as high as those who have [familial hypercholesterolemia],” a coauthor said in a statement.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n